Persistence of the Immune Response After Ebola Vaccine Immunisation

2017-05-05 11:53:22 | BioPortfolio


The Oxford University is undertaking a follow-on study to a Phase 1 study involving the two viral vectored Ebola vaccines Ad26-ZEBOV and MVA-BN-Filo. The aim of this study is to investigate the persistence of the vaccine induced immune response, 24 months after administration of the primary vaccination.


The Ebola Virus Disease (EVD), is caused by the viruses belonging to the genus Ebola virus. The disease occurs in sporadic outbreaks in the endemic zones of Africa and results in high mortality. During an outbreak, human to human to transmission occurs by contact with the body fluids of an infected individual. In the inter-endemic period the disease is zoonotically sustained in the environment. Prevention or control of future endemic outbreaks in the high risk areas of Africa will require effective preventative strategies including immunisation.

The Phase 1 study with the multiple heterologous prime boost regimes of the Ad26-ZEBOV and the MVA-BN-Filo vaccines demonstrated a substantive immunogenicity and safety of the vaccines. A combined immune response of humoral and cellular immunity was observed in the study participants. Furthermore, persistence of the immune response was evident at one year following the primary vaccination. It is not known whether the immune response persists beyond this time point. The duration of the immunological response is important as it will inform the clinical utility of the vaccines and whether or not additional booster dosage will be required and if so, at what interval.

In this study we will invite the 56 participants from the Phase 1 study at a time point between 24 months and 30 months of receiving the primary vaccination. Following consenting and enrolment into the study, the participants will undergo a blood test. We will assess the humoral immunity by estimating the level of binding antibody to the Ebola virus envelope glycoprotein. Cellular immunity will be assessed by estimating the functional CD4+ and the CD8+ T cells secreting the pro-inflammatory cytokines. We will undertake this assessment by intracellular staining of the peripheral blood mononuclear cells (PBMC) and using flowcytometry technique to identify the positively stained cells. A second assessment of the cellular immunity will be carried out by an in-house ELISpot technique subject to availability of additional funding.

Study Design


Ebola Virus Disease


Oxford Vaccine Group
United Kingdom


Enrolling by invitation


University of Oxford

Results (where available)

View Results


Published on BioPortfolio: 2017-05-05T11:53:22-0400

Clinical Trials [735 Associated Clinical Trials listed on BioPortfolio]

Evaluating an Ebola and a Margurg Vaccine in Uganda

This study will test two new vaccines, one for Ebola and one for Marburg virus, to see if they are safe, if they have side effects, and if they create an immune response in people who rece...

Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults

The purpose of this study is to assess the safety profile of the Zaire Ebola vaccine and the strength of the immune response.

A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine

A Single-Center, Randomized, Blind, Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV) in Health...

R3470-3471-3479 Expanded Access Protocol (EAP) for Treatment of Ebola

Provide individual access to treatment for Zaire Ebola virus disease (EVD) or post-exposure prophylaxis after high-risk exposure to Zaire ebolavirus (EBOV) with the investigational product...

Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine

Interventional, single arm, open-label, non-randomized, phase IIIb study to accumulate additional data on safety and effectiveness of one dose of rVSVΔG-ZEBOV-GP against Ebola virus disea...

PubMed Articles [17976 Associated PubMed Articles listed on BioPortfolio]

Development of a screening eye clinic for Ebola virus disease survivors: Lessons learned and rapid implementation at ELWA Hospital in Monrovia, Liberia 2015.

In the wake of the West African Ebola virus disease (EVD) outbreak of 2014-2016, thousands of EVD survivors began to manifest a constellation of systemic and ophthalmic sequelae. Besides systemic arth...

Adherence to Universal Travel Screening in the Emergency Department During Epidemic Ebola Virus Disease.

During the 2014 West African Ebola Virus Disease (EVD) outbreak, the U.S. Centers for Disease Control and Prevention recommended that all emergency department (ED) patients undergo travel screening fo...

Barriers to supportive care during the Ebola virus disease outbreak in West Africa: Results of a qualitative study.

During the 2013-2016 West Africa Ebola outbreak, supportive care was the only non-experimental treatment option for patients with Ebola virus disease (EVD). However, providing care that would otherwis...

Antibody-mediated virus neutralization is not a universal mechanism of Marburg, Ebola or Sosuga virus clearance in Egyptian rousette bats.

Although bats are increasingly being recognized as natural reservoir hosts of emerging zoonotic viruses, little is known about how they control and clear virus infection in the absence of clinical dis...

Tip Your Cap for Ebola Virus Neutralization.

Outbreaks of Ebola virus disease are caused by multiple virus species although current therapeutic monoclonal antibodies (mAb) are essentially limited to treating one species, Zaire ebolavirus. In thi...

Medical and Biotech [MESH] Definitions

An Ig domain-containing membrane receptor for HEPATITIS A VIRUS; EBOLA VIRUS; MARBURG VIRUS; and DENGUE VIRUS. It may also function to modulate ASTHMA and HYPERSENSITIVITY.

A highly fatal, acute hemorrhagic fever, clinically very similar to MARBURG VIRUS DISEASE, caused by EBOLAVIRUS, first occurring in the Sudan and adjacent northwestern (what was then) Zaire.

Vaccines or candidate vaccines used to prevent EBOLA HEMORRHAGIC FEVER.

A genus of FLAVIVIRIDAE, also known as mucosal disease virus group, which is not arthropod-borne. Transmission is by direct and indirect contact, and by transplacental and congenital transmission. Species include BORDER DISEASE VIRUS, bovine viral diarrhea virus (DIARRHEA VIRUS, BOVINE VIRAL), and CLASSICAL SWINE FEVER VIRUS.

A genus in the family FILOVIRIDAE consisting of several distinct species of Ebolavirus, each containing separate strains. These viruses cause outbreaks of a contagious, hemorrhagic disease (HEMORRHAGIC FEVER, EBOLA) in humans, usually with high mortality.

More From BioPortfolio on "Persistence of the Immune Response After Ebola Vaccine Immunisation"

Quick Search


Relevant Topics

Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...

Searches Linking to this Trial